 Published in the TOWNSEND LETTER for DOCTORS - JUNE 1994 pages 606 -607 View Accompanying Graph Suppression of Frequently Recurring Herpes Introduction: The suppression of frequently recurring herpes, bythe delivery of homeopathic medications via audio cassette technology.A placebo-controlled double blind trial. By Michael Kelly, President, ThoughtForms Corporation With the invention of electroacupuncture according to Voll,(EAV, Germany 1953), and later improvements such as the MORA-TherapyUnit (1975); it us now possible for health care practitioners toadminister homeopathic remedies electronically.EAV technology transfers the remedies, i.e. swallowing, orhaving a substance injected into their physical body. All of this ispossible without affecting the nature of potency of the original testset of homeopathic remedies used by the practitioner!ThoughtForms Corporation of Minneapolis has developed asimilar patented process to transfer homeopathic remedies onto audiocassette tapes. Just as a liquid homeopathic remedy can be produce in apill form, ThoughtForms Corporation has taken the liquid and producedit in a electronic form on magnetic tapes for use by the general publicwhich eliminates the need for repurchasing the product at a later datefor repeated use.Summary of A Placebo-Controlled Double Blind Trial of Michael Kelly's Audio Cassette Technology. Conducted by Donald Soli, M.D. Abstract Twenty-six other wise healthy adults with frequentlyrecurring herpes, both simple-1 and simmple-2 (>6 episodes peryear). Were studied in a double blind trial comparing two audiocassettes provided by Michael Kelly, for the suppression of recurrentherpes infections. The patients were treated five times during the 60days unless herpes recurred. If the patients experienced a recurrentinfection they were seen at the clinic within 24-48 hrs, examined, andtreated again with their assigned audio cassette. Twenty-three patientscompleted the testing. Among the 23 evaluable patients, there weresignificantly fewer recurrences (3 out of 4) in patients using the tapeK (real) than in patients using the tape M / placebo tape (8 out of 10)The duration of therapy (60 days) was the same for all patients. It was concluded that Michael Kelly's tape K (real tape)suppresses simplex-1 and simplex -2 herpes in patients with frequentrecurrences.Due to the limited duration of testing, it was unknownwhether the tape eliminates the latent virus in nerve ganglia i.e.whether the infection recurs after treatment. Despite this limitation,this study suggests that Michael Kelly's audio is useful for thesuppression of expected herpetic recurrences.Methods Study Population All patients studied were other wise healthy patientsbetween 17 and 60 years of age who had reported 6 or more recurrencesin the past year, and who agreed to abstain form using any othermedications or treatment methods, and agreed to practice effectivemethods of birth control.Study Design Mr. Kelly provided me with a tape "K" and a tape "M" . Iwas further informed that one of the tapes was a placebo while theother contained Mr. Kelly's remedies, but was not informed as tow whichwas which. Both tapes contained the sound of relaxing music and thesound of running water and were apparently identical in length.Appearance, and sound. At the initial visit, informed consent andmedical histories were obtained, suspected lesions were examined, andthe patients were assigned to the tape "K" or the tape "M". Two codedaudio cassettes were used in the medical office with each visit byvolunteers. One cassette tape was identified as (M) and one wasidentified as cassette (K). The first three consecutive days eachvounteer was tested and treated and then scheduled to return once permonth for two additional visits. During the first visit after a medicalhistory was taken, each person had blood drawn and then they weretested with Voll's Dermatron, a diagnostic device that measureselectrical energy emitted by acupuncture points. After measurementswere taken all patients were instructed to listen once to the assigned20-minute cassette with headphones. Each patient has handed thecassette by the physician's assistant and then listened to the cassetteonce per day, with each visit when they arrived in the clinic for testin during the first three days of the study. Clinic visits werescheduled once every 4 weeks. Additional visits were arranged as neededto evaluate suspected recurrences within 24 hours after onset. In theabsence of a recurrence, the only treatment given every four weeks waslistening to the audio tape once every month in the medical office. Theentire test period was 60 day. We continue to monitor the patients withmonthly phone interviews regarding any changes in the frequency ofrecurrences. A recurrence was diagnosed clinically when a patentpresent with typical symptoms and a number of vesicles, pustules, oarulcers. Each patient was checked with the Voll Dermatron.On confirmation of a recurrence (clinically) patientsimmediately were tested with the Dermatron and then treated with theirassigned cassette either (K) or (M).At the conclusion of the study, I opened an envelope thathad been provided to me by Mr. Kelly prior to the study. The lettertherein identified the "K" tape as the authentic treatment and the "M"tape as the placebo.Monitoring of Toxicity and Compliance At all visits, the subjects were questioned regardingsigns or symptoms of herpetic disease, as well as any negativereactions to the treatment. There were no complaints about negativereactions from anyone in the (K) group. At each scheduled visit, eachpatient was tested with Dermatron and each then listened to theirassigned tape.Virus Isolation Viral identification was conducted with the Dermatron andblood test were taken on the first visit and on the last visit. Due tothe late date that testing was completed, these test have not beenanalyzed or reviewed.Results Twenty-six patients were enrolled in the study.Twenty-three patients completed the treatment. The data form threepatients were not included in the analysis of the results of treatment.Two women using the treatment tape (K) withdrew from the study, and oneman using the placebo tape (M) withdrew. None of those who withdrewreported any outbreaks of the herpes virus before discontinuing.Effects of Treatment Table 2 shows the outcome of treatment of the study. Significantly fewer patients (3 patientsin the tape (K) group vs. 8 in the (M) group) experienced recurrences.Patient Statements The positive experiences of four patients are noteworthy.The one woman n the (K) group who experienced a recurrence stated " Iusually have outbreaks one week after my period. Normally it takes onweek to scale over and dry up. It was amazing how it was down, asmaller breakout, clearing and gone in three days." A man, who startedto have a recurrence on his lower lip stated, " it didn't materialize."Another stated normally he would have had two additional recurrences bynow instead of actually experiencing none. A third man in the (K) group experienced and outbreak thesecond day the test began. He healed in two days and stated, "this isthe quickest it has ever healed." Since his infection occurred on thesecond day of the test, within the first three days of the test, it wasnot counted as a failure of the (K) tape. Another man in the (K) groupwho did not experience any recurrence stated "in the past month I wouldhave normally had 2 out breaks, but nothing!"Eleven out of 26 patients experienced recurrences. Allrecurrences were confirmed with clinical visits. Of these 11, 8patients had used the placebo tape (M), and they had a total of 10recurrences combined. Two patients from the tape (K) had recurrences, 2outbreaks each.Moreover, the mean times for healing from the onset of thefirst recurrence after the start of treatment were significantlyshorter in the tape (K) group. Two patients said they healed in 57%less time (3 days instead of 7), and 50% less (3 days instead of 6),the third one healed at his normal rat of 6 days. In the blind study, the (K) tape treatment failed in twoof eight men and in one of three women. In the (M) group 5 women and 3men had recurrences.The Average Length of Recurrence Prior to treatment, the patients reported their average duration of outbreaks as follows:(M) Group = 11.58, 139 total days, 12 patients(K) Group = 8.36, 92 total days, 11 patientsDuring treatment, the patients reported their average duration of outbreaks as follows:(M) Group = 7.75 days, 62 total days / 8 patients 33.07% improvement(K) Group = 4.66 days, 14 days total / 3 patients 44.25% improvementIt is believed some improvement in both groups isattributed to the relaxing nature of the music on both tapes as well asheightened expectations.Additional Sample Data Prior to test, the number of days most recent recurrence lasted: Group (M) total 120 days, average 10Group (K) total 98, average 8.9The average age of the male and female participantsMen's average age = 33.34, low = 17, high = 58, total = 206Women's average age = 28.8, low =20, high = 53, total = 173The number of males 14, and females 12, 3 females dropped out.Group (M) females 7, males 6, 1 female dropped outGroup (K) females 5, males 8, 2 females dropped outNumber of patients experiencing simplex-1, oral, or genital herpes, simplex-2Group (M) 8 had simplex-1, 4 had simplex-2Group (K) 5 had simplex-1, 2 had simplex-2 and 2 patients had both simplex 1 & 2.
None of the patients had more vesicles or reported moresevere symptoms during the treatment recurrence than they recalledhaving had during their more recent pretreatment episodes.In the (K) group there was two reports of tingling,characteristic of incipient recurrences: however, lesions did no tdevelop. After completing the treatment, all patients received copiesof the tape containing the proper sound frequencies.Compliance Compliance was verified by visits to the medical officeand that is the only time patients had access to use the audio cassettetapes.Two female patients moved out of state and were unable tocomplete the test. Another female patient dropped out of the studyafter being physically abused by her husband.Adverse Reactions No problems, related to treatment were reported by patients with returning visits of each treatment phase.I hereby declare that the foregoing is an accurate summaryof testing conducted under my control and supervision and that I am adisinterested third party with respect to Michael Kelly's tape.
- Donald E. Soli, M.D. February 23, 1993Published in the TOWNSEND LETTER for DOCTORS - JUNE 1994 pages 606 -607 |
